Zymeworks ZYME Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research and development collaborations by Product | ||||||
| Development support payments | $392K-91.3% | $296K— | $352K-53.9% | $475K-57.2% | $4.49M+117% | |
| Drug supply for ongoing studies | $345K-88.3% | $780K-79.3% | $970K-81.6% | $1.84M-53.8% | $2.96M-52.4% | |
| Milestone revenue | $0-100% | —— | $25M+900% | $20M+150% | $14M— | |
| Other drug supply | $117K-94.6% | $0-100% | $71K-98.8% | $7K-99.9% | $2.15M+36.2% | |
| Royalties | $1.33M+558% | $898K+798% | $831K— | $550K— | $202K— | |
| R&D by Product | ||||||
| Expense for other preclinical and research programs | $7.26M+19.6% | —— | —— | —— | $6.08M— | |
| Zanidatamab | $623K-55.6% | —— | —— | —— | $1.4M— | |
| ZW171 | $1.15M-48.4% | —— | —— | —— | $2.23M— | |
| ZW191 | $3.03M+77.7% | —— | —— | —— | $1.71M— | |
| ZW220 | $97K-95.6% | —— | —— | —— | $2.2M— | |
| ZW251 | $1.91M-51.7% | —— | —— | —— | $3.95M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zymeworks break its business down?
- Zymeworks (ZYME) reports research and development collaborations by product across 5 parts — Development support payments, Drug supply for ongoing studies, Milestone revenue, Other drug supply and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Zymeworks's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zymeworks's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.